Claims
- 1. A compound of the formula I in which:R1 is 1. (C1-C14)-alkyl, 2. (C2-C6)-alkenyl, 3. (C0-C6)-alkyl-(C3-C10)-cycloalkyl-(C0-C6)-alkyl, where the alkyl moiety is unsubstituted or substituted by one or more OH groups, 4. (C0-C6)-alkyl-(C6-C14)-aryl, 5. (C0-C6)-alkyl-(C3-C9)-heteroaryl, 6. (C2-C6)-alkenyl-(C6-C14)-aryl, 7. (C2-C6)-alkenyl-(C3-C9)-heteroaryl, 8. (C1-C6)-alkanoyl, or 9. a radical as defined under 4., 5., 6. or 7., where the (C6-C14)-aryl or (C3-C9)-heteroaryl moiety is substituted by 1, 2 or 3 identical or different radicals selected from the group consisting of (C1-C10)-alkyl, carboxyl, amino, nitro, (C1-C4)-alkylamino, hydroxyl, (C1-C4)-alkoxy, where one to all hydrogen atoms can be replaced by fluorine atoms, (C6-C12)-aryloxy, halogen, cyano, di-(C1-C4)-alkylamino, carbamoyl, sulfamoyl and (C1-C4)-alkoxycarbonyl, or two adjacent radicals on the (C6-C12)-aryl ring together are alkylenedioxy; R2 is hydrogen, (C1-C10)-alkyl, (C0-C6)-alkyl-(C6-12)-aryl or (C0-C6)-alkyl-(C3-C9)-heteroaryl, where the C6-C12-aryl or C3-C9-heteroaryl moiety is unsubstituted or substituted by 1, 2 or 3 identical or different radicals selected from the group consisting of carboxyl, amino, (C1-C4)-alkylamino, hydroxyl, (C1-C4)-alkoxy, halogen, cyano, di-(C1-C4)-alkylamino, carbamoyl, sulfamoyl and (C1-C4)-alkoxycarbonyl; R3 is —X—R4; X is —O—, —NR5— or —S—; R4 is defined as R1; or, alternatively to the definitions of R4 and R2 above, R4 together with R2 forms a bridge member —CH2—CH2— or —CH2—CH2—CH2—; R5 is hydrogen or (C1-C6)-alkyl; A is a fused cyclic ring system which a) is substituted by one, two or three oxo or hydroxyl functions, where one hydroxyl or oxo function is in the neighboring position to the dihydropyran ring, and b) is mono, di- or polysubstituted by a (C1-C10)-alkyl radical or a carboxyl group, where at least one alkyl substituent carries a functional group; or a physiologically tolerable salt thereof.
- 2. A compound as claimed in claim 1, wherein R1 is as defined under 9, and the two adjacent radicals on the (C6-C12)-aryl ring together are methylenedioxy.
- 3. A compound as claimed in claim 1, wherein A is a fused cyclic ring system which is substituted by one or two oxo or hydroxyl functions.
- 4. A compound as claimed in claim 1, wherein A is a fused cyclic ring system which is mono- or disubstituted by a (C1-C10)-alkyl radical or a carboxyl group.
- 5. A compound as claimed in claim 1, wherein A is a fused cyclic ring system that is mono- or di- or polysubstituted by a (C1-C10)-alkyl radical or a carboxyl group, where at least one alkyl substituent carries a hydroxyl, carboxyl, or amino group.
- 6. A compound as claimed in claim 1, wherein A is a fused cyclic ring system which is mono, di- or polysubstituted by a (C1-C10)-alkyl radical or a carboxyl group, where at least one alkyl substituent carries a hydroxyl, carboxyl or amino group.
- 7. A pharmaceutical composition comprising an effective amount of a compound as claimed in claim 1, together with a pharmaceutically suitable auxiliary.
- 8. A method for the treatment of a metabolic disorder comprising administering to a host in need of such treatment an effective amount of a compound as claimed in claim 1.
- 9. A method as claimed in claim 7, wherein the metabolic disorder is diabetes or arteriosclerosis.
- 10. A method for the treatment of a disorder of the cardiovascular system comprising administering to a host in need of such treatment an effective amount of a compound as claimed in claim 1.
- 11. A method for the treatment of a disorder of the central nervous system comprising administering to a host in need of such treatment an effective amount of a compound as claimed in claim 1.
- 12. A method for the treatment of a disorder of bone metabolism comprising administering to a host in need of such treatment an effective amount of a compound as claimed in claim 1.
- 13. A method for the treatment of cancer comprising administering to a host in need of such treatment an effective amount of a compound as claimed in claim 1.
- 14. A method for the treatment of an autoimmune disorder comprising administering to a host in need of such treatment an effective amount of a compound as claimed in claim 1.
- 15. A method for the treatment of infection comprising administering to a host in need of such treatment an effective amount of a compound as claimed in claim 1.
- 16. A compound as claimed in claim 1, in which the fused cyclic ring system A is 1,3-pyrimidine, benzene, dioxane or cyclohexane.
- 17. A compound as claimed in claim 1, in which the compound is a compound of formula or a physiologically tolerable salt thereof.
- 18. A compound as claimed in claim 1, in which the compound is a compound of the formula or a physiologically tolerable salt thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
196 24 154 |
Jun 1996 |
DE |
|
Parent Case Info
This is a continuation of application Ser. No. 09/202,558 filed on Dec. 17 1998, now abandoned which is a 371 national stage filing of PCT/EP97/03146, filed Jun. 18, 1997, all of which are incorporated herein by reference.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3775435 |
Sellstedt et al. |
Nov 1973 |
A |
5767116 |
Kerrigan et al. |
Jun 1998 |
A |
Non-Patent Literature Citations (3)
Entry |
Garrat, Vollhardt, Aromatizität, “7. Heterocyclische Systeme” pp. 131-153 (1973) Stuttgart. |
Früchtel et al., “Organic Chemistry on Solid Supports”, Agnew. Chem. Int. Ed. Engl. 35:17-42 (1996). |
L.F. Tietze, “Domino-Reactions: The Tandem-Knoevenagel-Hetero-Diels-Alder Reaction And Its Application In Natural Product Synthesis”, J. Heterocyclic Chem., 27(47):47-71 (1990). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09/202558 |
|
US |
Child |
09/609594 |
|
US |